{'52WeekChange': 0.26829267,
 'SandP52WeekChange': 0.0644362,
 'address1': '535 Boylston Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 26.07,
 'askSize': 1400,
 'averageDailyVolume10Day': 92500,
 'averageVolume': 162804,
 'averageVolume10days': 92500,
 'beta': None,
 'beta3Year': None,
 'bid': 25.96,
 'bidSize': 900,
 'bookValue': -59.908,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 26.91,
 'dayLow': 25.5,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -11.498,
 'enterpriseToRevenue': None,
 'enterpriseValue': 425378592,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 32.569714,
 'fiftyTwoWeekHigh': 53.11,
 'fiftyTwoWeekLow': 15.1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10522368,
 'forwardEps': -1.99,
 'forwardPE': -13.065327,
 'fromCurrency': None,
 'fullTimeEmployees': 13,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.12935,
 'heldPercentInstitutions': 0.86708,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aprea.com',
 'longBusinessSummary': 'Aprea Therapeutics, Inc., a biopharmaceutical '
                        'company, develops and commercializes cancer '
                        'therapeutics that reactivate mutant p53 tumor '
                        'suppressor protein. Its lead product candidate is '
                        'APR-246, a small molecule p53 reactivator that is in '
                        'late-stage clinical development for hematologic '
                        'malignancies, including myelodysplastic syndromes and '
                        'acute myeloid leukemia. The company was founded in '
                        '2006 and is headquartered in Boston, Massachusetts.',
 'longName': 'Aprea Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 547424768,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_636010818',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -33984864,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.62,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-463-9385',
 'previousClose': 25.67,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 26.91,
 'regularMarketDayLow': 25.5,
 'regularMarketOpen': 25.62,
 'regularMarketPreviousClose': 25.67,
 'regularMarketPrice': 25.62,
 'regularMarketVolume': 84752,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 20990500,
 'sharesPercentSharesOut': 0.0493,
 'sharesShort': 1038818,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 743847,
 'shortName': 'Aprea Therapeutics, Inc.',
 'shortPercentOfFloat': 0.17889999,
 'shortRatio': 3.75,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'APRE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -26.67,
 'twoHundredDayAverage': 34.033237,
 'volume': 84752,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aprea.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02116'}